Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Launches US Sales Team

Premium

Rosetta Genomics this week announced that it has established a US sales team that will handle the commercialization of its suite of microRNA-based diagnostics.

The team will particularly focus on Rosetta's miRview Mets and miRview Mets 2 tests, which are designed to determine the source of cancers of unknown primary origin.

Rosetta did not specify the size of the team, but said it will expand it “over the coming quarters.”

The move has long been expected after a dispute between Rosetta and its one-time US distribution partner Prometheus Laboratories resulted in the miRNA company regaining the market rights to its products (GSN 12/2/2010). Rosetta continues to sell its products through distributors outside of the US.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.